2025-12-28 - Analysis Report
Okay, here's a comprehensive analysis of TMDX (Transmedics Group Inc.) based on the provided data.

**1) Return Rate Comparison (vs. S&P 500)**

*   **TMDX Overview:** Transmedics Group Inc. is a medical technology company pioneering a novel approach to preserve and assess organs for transplant.
*   **TMDX Cumulative Return:** 205.68%
*   **S&P 500 (VOO) Cumulative Return:** 78.45%
*   **Divergence:** 138.1 (Relative Divergence: 66.1)

**Analysis:**

TMDX has significantly outperformed the S&P 500, generating over twice the return. The divergence between TMDX and the S&P 500 is substantial. The "Relative Divergence" of 66.1 indicates that the current divergence is in the higher range of its historical fluctuation.

**Alpha, Beta Analysis:**

|            | CAGR    | MDD    | Alpha   | Beta | Cap(B) |
|------------|---------|--------|---------|------|--------|
| 2019-2021  | -18.0%  | 83.5%  | -61.0%  | -0.0 | 0.7    |
| 2020-2022  | 94.0%   | 83.5%  | 95.0%   | 0.0  | 2.1    |
| 2021-2023  | 65.0%   | 80.5%  | 64.0%   | 0.1  | 2.7    |
| 2022-2024  | 130.0%  | 85.5%  | 109.0%  | 0.1  | 2.1    |
| 2023-2025  | 126.0%  | 85.5%  | 59.0%   | 0.3  | 4.2    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Shows strong growth in recent periods (2020-2025).
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant volatility and risk.
*   **Alpha:** Generally very high, suggesting TMDX is generating returns independent of the market. The alpha dropped significantly between 2022-2024 and 2023-2025.
*   **Beta:** Low, indicating that the stock is not very correlated with the S&P 500.
*   **Cap(B):** Market capitalization steadily grew from 2019 to 2025.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 124.20
*   **Previous Close:** 126.99
*   **Change:** -2.2
*   **5-day SMA:** 127.28
*   **20-day SMA:** 131.54
*   **60-day SMA:** 125.80

**Analysis:**

The stock price has recently declined, as evidenced by the negative change from the previous close. The 5-day and 20-day SMAs are above the current price, suggesting a short-term downward trend. The 60-day SMA is slightly above the current price and may serve as possible support.

**3) Indicators Analysis**

*   **MRI (Market Risk Indicator):** 1.0 (High Investment Recommended)
*   **RSI:** 31.25 (Approaching Oversold)
*   **PPO:** -0.66 (Negative, indicating a possible downtrend)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90)
*   **Recent Relative Divergence Change:** 0.6 (+): 단기상승 (Short-term increase)
*   **Expected Return:** 47.6% (Significant excess return expected compared to S&P 500 over 2+ years)

**Analysis:**

The MRI suggests a high investment recommendation, but this should be viewed with caution considering other indicators. The RSI is nearing oversold territory, which *could* indicate a potential buying opportunity, but further confirmation is needed. The negative PPO supports the short-term downtrend seen in the moving averages. The Hybrid Signal recommends buying. The recent increase in relative divergence suggests a potential for short-term gains, despite the recent price decrease. The high Expected Return is a significant positive factor.

**4) Recent News & Significant Events**

*   **Positive Headlines:**
    *   "Here's Why TransMedics (TMDX) is a Strong Growth Stock"
    *   "TransMedics Stock: I Estimate An Upside Of Nearly 150% By The End Of 2028"
    *   "Here Are My Top 2 No-Brainer Growth Stocks to Buy Now"

*   **Neutral/Mixed Headlines:**
    *   "New TransMedics hires get stock options and units with long vesting" (Generally positive for attracting talent, but dilutes existing shares)
    *   "Behavioral Patterns of TMDX and Institutional Flows" (Needs further investigation to understand the implications)

*   **Negative Headlines:**
    *   "Insider Selling: TransMedics Group (NASDAQ:TMDX) CFO Sells 920 Shares of Stock" (Can be a negative signal, though not always a major concern)

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.67)
*   **Opinions:** 11
*   **Target Price:** Avg: 144.73 / High: 170.00 / Low: 114.00
*   **Recent Rating Changes:** No changes provided.

**Analysis:**

The analyst consensus is strongly bullish, with a "Buy" rating and a significant average target price above the current market price. This suggests analysts believe the stock is undervalued.

**5) Comprehensive Analysis (Summary)**

TMDX has shown exceptional growth and significantly outperformed the S&P 500. Its high Alpha and growth rates suggest it's a strong performer. However, the high MDD indicates substantial volatility.

**Key Points:**

*   **Positive:** High expected returns, strong historical growth, positive analyst ratings, and several positive news headlines.
*   **Mixed:** Recent stock price decline, negative short-term indicators (PPO, SMA relationships), and insider selling.
*   **Risks:** High volatility (MDD), competition in the medical technology space.

**Conclusion:**

Despite recent price weakness, TMDX appears to be a promising growth stock. The analyst consensus and positive news reinforce this view. The high expected return and significant potential upside identified by some analysts make it an attractive investment. However, investors should be aware of the high volatility and recent downward trend, and potentially wait for confirmation of reversal before investing. The insider selling should be monitored, but is not necessarily a reason to avoid the stock entirely. The MRI, while indicating high investment recommendation, should be considered with the other indicators. A diversified investment strategy is always recommended, especially with volatile stocks.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.